Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial

The SINGLE study was a randomized, double-blind, noninferiority study that evaluated the safety and efficacy of 50 mg dolutegravir + abacavir/lamivudine versus efavirenz/tenofovir/emtricitabine in 833 ART-naive HIV-1 + participants. Of 833 randomized participants, 71% in the dolutegravir + abacavir/...

Descripción completa

Detalles Bibliográficos
Autores principales: Walmsley, Sharon, Baumgarten, Axel, Berenguer, Juan, Felizarta, Franco, Florence, Eric, Khuong-Josses, Marie-Aude, Kilby, J. Michael, Lutz, Thomas, Podzamczer, Daniel, Portilla, Joaquin, Roth, Norman, Wong, Deborah, Granier, Catherine, Wynne, Brian, Pappa, Keith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2015
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645960/
https://www.ncbi.nlm.nih.gov/pubmed/26262777
http://dx.doi.org/10.1097/QAI.0000000000000790
Descripción
Sumario:The SINGLE study was a randomized, double-blind, noninferiority study that evaluated the safety and efficacy of 50 mg dolutegravir + abacavir/lamivudine versus efavirenz/tenofovir/emtricitabine in 833 ART-naive HIV-1 + participants. Of 833 randomized participants, 71% in the dolutegravir + abacavir/lamivudine arm and 63% in the efavirenz/tenofovir/emtricitabine arm maintained viral loads of <50 copies per milliliter through W144 (P = 0.01). Superior efficacy was primarily driven by fewer discontinuations due to adverse events in the dolutegravir + abacavir/lamivudine arm [dolutegravir + abacavir/lamivudine arm, 13 (3%); efavirenz/tenofovir/emtricitabine arm, 48 (11%)] through W144. No treatment-emergent integrase or nucleoside resistance was observed in dolutegravir + abacavir/lamivudine recipients through W144.

Ejemplares similares